Festschrift in honor of Andrew L. Warshaw, M.D.

Saturday, October 29, 2011
O'Keefe Auditorium
Massachusetts General Hospital

7:00 am – 7:40 am  Registration and Continental Breakfast, Lobby

7:40 am  Welcome and Introductory Remarks
Keith D. Lillemoe

7:45 am – 7:55 am  Why a Festschrift for Andy Warshaw?
David W. Rattner

7:55 am – 8:45 am  Session I: Pancreatic Cancer: Basic and Translational Research
Moderator: Ashok Saluja, M.D.

Jennifer A. Wargo, M.D.  Targeting the Mage A-3 antigen in pancreatic cancer
Jan Schmidt, M.D.  The role of tumor endothelium in leukocyte recruitment in pancreatic cancer.
William Hawkins, M.D.  Seek and destroy: Sigma-2 ligands as novel strategy to target pancreatic cancer.
Sarah P. Thayer, M.D., Ph.D.  Sonic Hedgehog in Pancreatic Cancer: From the bench to the bedside, now back to the bench

8:45 am – 10:20 am  Session II: Pancreatic Cancer: Clinical Research
Moderator: David P. Ryan, M.D.

Oliver Stroebel, M.D.  Resection after neoadjuvant therapy for primarily unresectable pancreatic cancer
Stefano Crippa, M.D.  Poorly differentiated resectable pancreatic cancer: is upfront surgery worthwhile?
Ernst Klar, M.D.  R0 resection in pancreatic cancer has an impact on long-term outcome, even in routine histologic examination
Wolfram T. Knoefel, M.D.  Vascular invasion in pancreatic cancer: tumor biology or tumor topography?
Philip J. Spencer, M.D.  Safety and feasibility of proton beam neoadjuvant chemoradiation for resectable adenocarcinoma of the pancreatic head: Surgical outcomes of a phase I/II trial and comparison to contemporary patients treated initially with pancreatoduodenectomy
Werner Hartwig, M.D.  Cachexia in pancreatic cancer
Cristina Ferrone, M.D.  5-year survivors of pancreatic cancer: what can we learn from them?

10:20 am – 10:40 am  Coffee Break, Lobby of the auditorium

10:40 am – 12:10 pm  A Symposium on Intraductal Papillary Mucinous Neoplasms
Moderator: Carlos Fernández-del Castillo, M.D.

C. Fernández-del Castillo, M.D.  Introduction
Why are pathologists classifying and sub-classifying IPMNs?

What can a radiologist tell you about your patient with IPMN?

Can EUS determine if an IPMN should be observed or taken out? Can it treat it?

Short- and long-term outcomes of surgery for IPMN

A possible site of origin of IPMNs

Lunch, East Room

Session III: Acute and Chronic Pancreatitis

Minimally invasive procedures for acute necrotizing pancreatitis: comparison of minimally invasive retroperitoneal necrosectomy and transgastric endoscopic drainage

The role of calcium in acute pancreatitis

Short- and long-term results of duodenum preservation vs resection for the management of chronic pancreatitis: a prospective randomized study

Session IV: Cystic disease of the Pancreas

851 resected cystic tumors of the pancreas: a 33-year experience at the MGH

Multifocal IPMNs

Pancreatic resections for cystic neoplasms: from the surgeon's presumption to the pathologist's reality

Coffee break, Lobby

Session V: Pancreatic Surgery

Can we adequately predict risk for pancreatic surgery?

Volume in Pancreatic Surgery: the situation in Germany

Techniques for pancreatic stump closure after distal pancreatectomy: can we pick a winner?

Reduction of clinically-relevant pancreatic fistula rate by additional coverage of the pancreatic remnant after distal pancreatectomy

History of the Whipple procedure at the MGH

Dissemination of a master surgeon: Study on the properties of an extraordinary individual

Concluding Remarks: Andrew L. Warshaw, M.D.